Literature DB >> 7975717

Characterization of the inhibition of P4501A2 by furafylline.

S E Clarke1, A D Ayrton, R J Chenery.   

Abstract

1. Furafylline inhibition of 1A2-related activity in human liver microsomal systems was characterized. This inhibition was time and NADPH dependent. The kinetic constants were measured in human liver microsomes; a Ki of inactivation of 3 microM with a maximum rate constant of 0.27 min-1 were determined. 2. This inactivation process was retarded by the presence of a 1A2 substrate and after complete inhibition was achieved, 1A2 activity could be restored by the addition of fresh microsomes to the incubation mixture. These results are consistent with furafylline being a suicide substrate for 1A2. 3. Preincubating microsomes for 10 min with 10 microM furafylline in the presence of NADPH, prior to the initiation of the reaction by the addition of substrate, caused marked inhibition of 1A2 activity. This protocol was tested for specificity against 10 human P450 activities. The activities associated with 1A1, 2A6, 2B6, 2C9(/8), 2C19, 2D6, 2E1, 3A4(/5) and A were not significantly inhibited. 4. Using these conditions furafylline can be diagnostic of 1A2 involvement in a P450-dependent oxidative reaction.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7975717     DOI: 10.3109/00498259409043254

Source DB:  PubMed          Journal:  Xenobiotica        ISSN: 0049-8254            Impact factor:   1.908


  8 in total

Review 1.  Reaction phenotyping: current industry efforts to identify enzymes responsible for metabolizing drug candidates.

Authors:  Timothy W Harper; Patrick J Brassil
Journal:  AAPS J       Date:  2008-04-05       Impact factor: 4.009

2.  Cytochromes P450 1A2 and 3A4 Catalyze the Metabolic Activation of Sunitinib.

Authors:  Gracia M Amaya; Rebecca Durandis; David S Bourgeois; James A Perkins; Arsany A Abouda; Kahari J Wines; Mohamed Mohamud; Samuel A Starks; R Nathan Daniels; Klarissa D Jackson
Journal:  Chem Res Toxicol       Date:  2018-06-18       Impact factor: 3.739

3.  Effects of furanocoumarins from apiaceous vegetables on the catalytic activity of recombinant human cytochrome P-450 1A2.

Authors:  Ah-Young Kang; Lindsay R Young; Carlus Dingfelder; Sabrina Peterson
Journal:  Protein J       Date:  2011-10       Impact factor: 2.371

Review 4.  Chemical inhibitors of cytochrome P450 isoforms in human liver microsomes: a re-evaluation of P450 isoform selectivity.

Authors:  Siamak Cyrus Khojasteh; Saileta Prabhu; Jane R Kenny; Jason S Halladay; Anthony Y H Lu
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2011-02-19       Impact factor: 2.441

5.  Characterization of the cytochrome P450 enzymes involved in the in vitro metabolism of rosiglitazone.

Authors:  S J Baldwin; S E Clarke; R J Chenery
Journal:  Br J Clin Pharmacol       Date:  1999-09       Impact factor: 4.335

6.  Involvement of CYP1A2 in mexiletine metabolism.

Authors:  M Nakajima; K Kobayashi; N Shimada; S Tokudome; T Yamamoto; Y Kuroiwa
Journal:  Br J Clin Pharmacol       Date:  1998-07       Impact factor: 4.335

7.  In vitro metabolism and drug-drug interaction potential of UTL-5g, a novel chemo- and radioprotective agent.

Authors:  Jianmei Wu; Jiajiu Shaw; Sarah Dubaisi; Frederick Valeriote; Jing Li
Journal:  Drug Metab Dispos       Date:  2014-09-23       Impact factor: 3.922

Review 8.  Strategies and molecular probes to investigate the role of cytochrome P450 in drug metabolism: focus on in vitro studies.

Authors:  M Teresa Donato; José V Castell
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 5.577

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.